Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT04164758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04164758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 23, 2019
Completion date
September 25, 2020
Enrollment
11 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease